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Experiments performed in mice revealed that anthracyclines stimulate immunogenic cell death that is characterized by the
pre-apoptotic exposure of calreticulin (CRT) on the surface of dying tumor cells. Here, we determined whether CRT exposure at
the cell surface (ecto-CRT) occurs in human cancer in response to anthracyclines in vivo, focusing on acute myeloid leukemia
(AML), which is currently treated with a combination of aracytine and anthracyclines. Most of the patients beneﬁt from the
induction chemotherapy butrelapsewithin 1–12months.Inthisstudy, weinvestigatedecto-CRTexpression onmalignant blasts
before and after induction chemotherapy. We observed that leukemic cells from some patients exhibited ecto-CRT regardless of
chemotherapy and that this parameter was not modulated by in vivo chemotherapy. Ecto-CRT correlated with the presence of
phosphorylated eIF2a within the blasts, in line with the possibility that CRT exposure results from an endoplasmic reticulum
stress response. Importantly, high levels of ecto-CRT on malignant myeloblasts positively correlated with the ability
of autologous T cells to secrete interferon-c on stimulation with blast-derived dendritic cell. We conclude that the presence of
ecto-CRT on leukemia cells facilitates cellular anticancer immune responses in AML patients.
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An optimally efﬁcient anticancer therapy can be achieved
bydestroyingeachcancercell.However,weknowthatalong-
lasting disease-free survival is not easy to achieve, presum-
ably because some tumor (stem) cells escape from therapy
and may remain dormant for months, years and some-
times decades. One strategy that might improve therapeutic
outcome relies on combination of potent cytotoxic chemo-
therapeutics and the induction of antitumor immune res-
ponses that control residual disease.
At the theoretical level, chemotherapy and immunotherapy
are difﬁcult to be reconciled because chemotherapy with
DNA-damaging agents often induces the massive destruction
of immune effectors. Owing to this immunosuppressive side
effect, it is intrinsically difﬁcult to elicit immune responses
against tumor antigens in patients after several cycles of
chemotherapy.
1 Moreover, apoptosis seems to be the
principal cell death mechanism induced by chemotherapy,
and apoptosis is mostly viewed as a non-immunogenic (or
even tolerogenic) cell death modality. Indeed, billions of cells
succumb to apoptosis every day in healthy individuals yet do
not provoke any signs of autoimmunity.
2 However, a recent
series of papers has demonstrated that some chemother-
apeutic agents, in particular anthracyclines and oxaliplatin,
areuniqueintheircapacitytoinduceimmunogeniccancercell
death in mice. These studies unraveled the molecular mecha-
nisms that distinguish immunogenic from non-immunogenic
cell death. The immunogenicity of cell death relies on at least
three independent events, namely (i) the early exposure of
calreticulin (CRT) on the cell surface of stressed cells (ecto-
CRT)
3 and the subsequent (ii) adenosine tri-phosphate
(ATP)
4 secretion and (iii) high mobility group box 1 (HMGB1)
release
5 by dying tumor cells. Membrane-exposed ecto-CRT
favorstheengulfmentoftheapoptoticbodiesbydendriticcells
(DCs), while HMGB1 and ATP modulate DC-mediated tumor
antigenpresentationandT-cellpolarization.
4Ofnote,thevast
majority cytotoxic agents fail to induce CRT exposure, while
only a few such as anthracyclines and oxaliplatin are able to
induce ecto-CRT. Knockdown of CRT, blockade of ecto-CRT
or inhibition of the pathway leading to CRT exposure
abolishes the immunogenicity of cell death elicited by
anthacyclins or oxaliplatin.
3 Normally, CRT is present in the
lumen of the endoplasmic reticulum (ER). In response to
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www.nature.com/cddisspeciﬁc ER stresssors, the eukaryotic translation initiation
factor 2a (eIF2a) becomes phosphorylated, thus enabling the
so-called integrated stress response that is linked to a
translational arrest.
6 This eIF2a phosphorylation is also
essential for CRT exposure because cells that lack the eIF2a
kinase, hyperactivate the eIF2a phosphatase or contain a
non-phosphorylatable eIF2a mutant fail to expose CRT in
response to anthracyclines or oxaliplatin.
7,8
The induction of T cells responses against leukemic cells
has been shown to ameliorate the therapeutic outcome in
patients with acute myeloid leukemia (AML) who were treated
with allogenic hematopoietic stem cells transplantation
(HSCT).
9 The success of HSCT is linked to a speciﬁc immune
response, the so-called graft-versus-leukemia reaction in
which transplanted T cells recognize leukemia-speciﬁc anti-
gens as well as minor histocompatibility antigens. It has been
suspected, yet remains to be conﬁrmed, that natural
autologous immune response may inﬂuence the clinical
course of AML. Thus, antibodies speciﬁc for leukemia-
associated antigens (LAAs) have been described, for exam-
ple, in promyelocytic leukemia.
10 Speciﬁc anti-leukemic
T lymphocytes have been identiﬁed in a few studies involving
AML patients.
11 It has been suspected that the presence of
these speciﬁc autologous T lymphocytes predicts a favorable
outcome.
11 Conversely, a high frequency of regulatory T cells
(CD4
þCD25
highFoxp3
þ Treg) is associated with a poor
outcome of AML therapy.
12 As compared with normal
volunteers, AML patients possess an elevated frequency of
Treg cells, which have an activated phenotype (with an
elevated expression of CTLA-4, GITR, perforin and granzyme
B), inhibit conventional T-cell proliferation ex vivo via IL-10
and TGFb1, and have an elevated capacity to hydrolyze ATP
(because of a high expression of the ecto-enzymes CD39 and
CD73).
12
Driven by these premises, we examined ecto-CRT expres-
sion on malignant blasts from AML patients, before and
after chemotherapy with anthracyclines. Importantly, we
found that a therapy-independent CRT exposure correlated
with the speciﬁc immune response of T lymphocytes against
autologous blast-derived DC. These results underscore the
clinical relevance of CRT exposure in the context of cancer
immunology.
Results
AML blasts can expose CRT (ecto-CRT) at their cell
surface regardless of chemotherapy. Anthracyclines are
capable of inducing immunogenic cancer cell death in mice.
2
Obeid et al.
3 showed that anthracyclines induce the
translocation of CRT from its orthotopic localization within
the lumen of ER vesicles to the surface of tumor cells (ecto-
CRT). Ecto-CRT is essential for the chemotherapy-mediated
induction of adaptive immune responses and the rejection of
tumors in mice. We therefore examined the membrane
translocation of CRT on malignant blasts from patients
treated with anthracyclines. The ﬂow cytometry analysis of
CRT expression on blast cells at the diagnosis, before
any treatment, revealed signiﬁcant (with a cut-off of 5%)
expression of membrane CRT in 10 of the 20 patients
(Figure 1a). The percentage of positive cells was rather
variable from one patient to the other, ranging from 5 to 95%.
In contrast, no upregulation of ecto-CRT expression was
observed on malignant blasts after anthracycline-based
chemotherapy (Figures 1b and c), except for two patients
(Figure 1b). Similar results were found at different time points
for several patients (data not shown), suggesting that CRT
exposure reﬂects a stable alteration of blasts. Moreover,
different leukemia cell lines (HL60, K562) or primary AML
blasts incubated with anthracylines (either doxorubicin or
idarubicin) in vitro for 1 to 4h, failed to translocate and/or
upregulate CRT to the plasma membrane (data not shown).
Peripheral blood mononuclear cell (PBMC) from healthy
volunteers (HVs) did not display any signiﬁcant ecto-CRT
expression, meaning that o5% of normal lymphocytes or
monocytes exposed CRT. No clinical or biological
characteristic of the AML patients was signiﬁcantly
associated with ecto-CRT expression in terms of age, white
blood count or the FAB type (Table 1).
An ELISA assay, which was performed on 16 of the 20
patients’ sera, detected high concentrations of soluble CRT,
compared with HVs, for 6 of the AML patients, all with high
white blood counts. No signiﬁcant correlation between the
CRT concentration and CRT exposure on the membrane of
the blasts could be highlighted (354±370 and 202±221ng/ml
for negative and positive ecto-CRT groups respectively,
P40.05). Moreover, no change of CRT concentration before
or after chemotherapy could be demonstrated (275±300
versus180±200ng/mlrespectively,P40.05).Incontrast,we
detectedapositivecorrelationbetweenserumCRTlevelsand
white blood cell counts (r¼0.5699, P¼0.0169), which may
reﬂect the spontaneous mortality of malignant blasts or,
alternatively, a nonspeciﬁc release of CRT from such cells.
The phosphorylation of eIF2a is associated with CRT
exposure of on the blasts membrane. The phosphory-
lation of eIF2a is a crucial event in the molecular pathway that
dictates the translocation of ER-resident CRT to the cell
surface,
8 we therefore analyzed the phosphorylation state of
malignant blast from AML patients that show spontaneous
CRT exposure and those that failed to expose CRT even
after treatment. Immunodetection of the phosphoneoepitope
using a speciﬁc antibody revealed that the spontaneous
CRT exposure on malignant blasts was associated with a
hyperphosphorylation of eIF2a (Figure 1d).
CD47 expression on leukemic blasts correlates inversely
with ecto-CRT. CD47 is an immunoglobulin-like protein that
interacts functionally with integrins and thrombspondin-1
(Gao et al.
13) and that participates in functions as diverse
as neutrophil migration,
14 axon extension
15 and T-cell
costimulation.
16 In addition, CD47 is capable of interacting
with its receptor signal-regulatory protein alpha (SIRPa)
17 on
macrophages to negatively regulate phagocytosis. Blockade
of CD47 expression results in phagocytosis of red blood
cells,
18 as well as T cells and whole bone marrow cells in a
transplant setting.
19 Thus, CD47 functions as a ‘don’t eat me’
signal to ensure that autologous cells are not inappropriately
phagocytosed. Intriguingly, two recent studies revealed that
CD47 is upregulated on leukemia cells
20 and represent an
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Cell Death and Diseaseadverse prognosis factor in AML.
21 Conﬁrming these data,
we found that in our cohort that CD47 expression was more
abundant on the surface of malignant blasts than on normal
monocytes (Figure 2a). However, by comparing the density
of CD47 expression between the two groups of patients that
were either ecto-CRT
pos or ecto-CRT
neg, we found that CD47
was weakly expressed among patients expressing ecto-CRT
(Figure 2b). In conclusion, the ‘eat me’ signal ecto-CRT
correlated inversely with the expression of the ‘don’t eat me’
signal CD47 in AML.
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Figure 1 Malignant myleoblasts from some AML patients spontaneously express CRT on their cell surface (ecto-CRT). (a) Representative FACS analyses of one patient
whoseblastsdonotexpressecto-CRT,neitherbeforenoraftertreatment(rightpanel),andanotherpatientwhoseblastsexpressecto-CRTevenbeforetreatment(leftpanel).
(b) Percentages of blasts expressing ecto-CRT, analyzed by ﬂow cytometry on blood samples before chemotherapy (previous) and 2–6h after chemotherapy. Statistical
analysis was performed using Wilcoxon’s test on matched pairs. (c) CRT exposure (red) has been evaluated in CD45-positive blast (green) from blood samples before and
afterchemotherapy by immunostainingand subsequentconfocal microscopy. Nuclei(blue) have been stained with DAPI.Scale bar represents2mm. (d) Blasts from different
patientshavebeen analyzedfor their eIF2a phosphorylation state. A representative immunoblot depictingthe phospho-eIF2a andis shown. A polyclonal antibodydetecting a
different epitope has been used to ensure equal loading
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Cell Death and DiseaseEcto-CRT is associated with an enhanced cellular
immune response against tumor antigens. To deter-
mine the inﬂuence of ecto-CRT on anti-leukemic immune
responses, we took advantage of DC derived from malignant
blasts (Figure 3a). Such leukemic DCs (AML-DC) constitutively
express tumor-associated antigens (TAAs)/LAAs as, for
example, the antigen preferentially expressed in melanoma
(PRAME), the Wilms tumor gene 1 or the receptor for
hyaluronic acid-mediated motility (CD168), which all can elicit
antigen-speciﬁc T-cell immune responses.
22–24 AML-DC can
stimulate autologous T cells for proliferation, interferon-g (IFNg)
secretion and cytotoxicity.
25 We comparatively assessed the
capacity of autologous T cells to secrete IFNg on exposure to
AML-DC in ecto-CRT
pos and ecto-CRT
neg patients. Puriﬁed
CD3
þ T lymphocytes from ecto-CRT
pos patients did produce
signiﬁcant levels of IFNg in responses to AML-DC (Figures 3b
and c, middle panel, P¼0.0078) but failed to do so in response
to non-differentiated blasts (Figures 3b and c, middle panel,
P40.05). This contrasts with the ecto-CRT
neg group, in which
autologous T cells were unable to upregulate IFNg production in
response to AML-DC (Figures 3b and c, right panel, P40.05).
Most HVs group exhibited a signiﬁcant auto-reactivity of their
T cells against autologous monocyte-derived DCs (mDCs;
Figures 3b and c, left panel, P¼0.0313).
Altogether, these data suggest a signiﬁcant link between
ecto-CRTexpressiononmalignantblastsatdiagnosisandthe
induction of Th1 responses.
Impact of ecto-CRT on the clinical evolution of
patients. Considering the small effective and the
heterogeneity of our cohort, we could not expect a
signiﬁcant association to one or another evolution
parameter. Accordingly, the overall survival of the patients
enrolled in this study did not correlate signiﬁcantly with
ecto-CRT levels (Figure 4a), although there was a trend
toward longer relapse-free survival for the ecto-CRT
neg group
Table 1 Clinical and biological characteristics in CRT
pos and CRT
neg group of patients
All CRT
pos (n¼10) CRT
neg (n¼10) P-value
Sex (m/f), n 9/11 5/5 4/6 40.5
Median age at diagnosis, years (range) 62 62 (26–77) 61 (28–82) 40.5
Median blasts in blood, % (range) 51 51 (3–95) 48.5 (5–85) 40.5
Median WBC ( 10
9/l) 27 35.5 (2.8–215) 22 (5–84) 40.5
De novo AML,n 1 6 8 7 40.5
Of which n relapse AML at the inclusion 3 1 2 40.5
Secondary AML
MPS/MDS, n 21
a 1
a 40.5
Therapy related, n 31
b 2
b 40.5
FAB classiﬁcation
M0 1 0 1 40.5
M1 3 1 2 40.5
M2 3 2 1 40.5
M3 1 0 1 40.5
M4 7 4 3 40.5
M5 5 3 2 40.5
M6, M7 0 0 0 40.5
FLT3 ITD, n 43 140.5
Cytogenetic proﬁle
Favorable 4 1 3 40.5
Intermediate 9 6 3 40.5
Unfavorable 5 1 4 40.5
unknown 2 2 0 40.5
Abbreviations: AML, acute myeloid leukemia; ecto-CRT
neg, no calreticulin expression; ecto-CRT
pos, membrane expression of calreticulin; MPS/MDs,
myeloproliferative/myelodysplastic syndrome
aTwo patients with chronic myelomonocytic leukemia
bPrevious chemotherapy and radiotherapy for throat and breast cancers
Figure 2 Ecto-CRT
pos blasts express less CD47 than ecto-CRT
neg blasts.
(a) Cytoﬂuorometric study of CD47 expression on circulating leukocytes from AML
patients. The mean ﬂuorescence intensity (MFI) of CD47 was determined by gating
on CD45
High CD3
þ lymphocytes (Ly) and CD45
low blasts (blasts) and compared
using a Wilcoxon’s test. (b)A si na but comparing the MFI of CD47 on CD45
low
blasts between ecto-CRT
pos (n¼10) and ecto-CRT
neg (n¼10) AML patients.
Statistical analysis was performed using the Mann–Whitney test. The dotted black bar
represents the average MFI of CD47 on the entire cohort of AML patients (n¼20)
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Cell Death and Disease(Figure 4b). As expected,
21 we found a trend for accelerated
relapses in patients with high CD47 expression
(mean ﬂuorescence intensity (MFI) Z100; median relapse-
free survival for patient reaching complete remission after
induction chemotherapy 11.23 months versus unreached for
patients with low CD47 expression (MFIo100)), although our
cohort was too small to detect a signiﬁcant effect of CD47
(P¼5229). Five patients relapsed in the ecto-CRT
neg group
(62.5%) versus two in the ecto-CRT
pos group (28.5%) with a
median follow-up of 40 months among patients who had
achieved a complete response after induction chemotherapy
(n¼7 for ecto-CRT
pos group and n¼8 for ecto-CRT
neg
group, Table 2). This trend in the relapse-free survival for
ecto-CRT
pos patients prompts us to extend this study to a
larger cohort.
Discussion
This clinical study has explored the putative link between
CRTcellsurfaceexpressionandanthracycline-basedchemo-
therapy in AML patients. Unexpectedly, we failed to produce
evidence that anthracyclines would induce CRT on the
surface of malignant blasts (Figure 1). Indeed, in half of the
AML cases, leukemic cells spontaneously exposed CRT on
their surface, correlating with the constitutive phosphorylation
of eIF2a (Figure 1d). This suggests that an ER stress
response that culminates in CRT exposure is constitutively
activated in a fraction of AML. Half of patients’ tumor cells
have activated this crucial mechanism favoring their uptake
by antigen-presenting cells (APCs).
3–5 This hypothesis
is strengthened by the observation that CD47 molecules
are less abundant on the surface of ecto-CRT
pos than on
ecto-CRT
neg blasts (Figure 2). Indeed, the reduced expres-
sion of the ‘don’t eat me’ signal (CD47), together with the
enhanced expression of the ‘eat me’ signal (ecto-CRT),
suggests that leukemic cells are efﬁciently engulfed by APCs
that then trigger an immune response against TAAs. Recent
reports have highlighted the fact that SIRPa could represent a
myeloid sensor for the ‘self’ molecule CD47.
26 SIRPa is an
inhibitory immunoreceptor that is selectively expressed by
myeloid lineage cells (macrophages, granulocytes and
myeloid DC), as well as neuronal cells.
27–29 The ligation of
SIRPa on macrophages (or other phagocytic cells expressing
this molecule) by CD47 expressed on non-phagocytic cells
generates an SHP-1-dependent inhibitory signal that sup-
presses phagocytosis.
30 Thus, low expression of CD47 on
malignantblastsshouldbecorrelatedwithabetterengulfment
bySIRPa-expressing cells.Moreover, ecto-CRT canfavor the
uptake of dying cells by DC, leading to efﬁcient T-cell priming
in vivo.
3 It is still unknown whether the candidate CRT
receptors CD91 and scavenger receptor class-A are required
for the DC-speciﬁc engulfment of CRT-exposing tumor
cells.
31 Taken together, these data provide a rational to
suggest that in AML, leukemic cells that express ecto-CRT
and low levels of CD47 could be engulfed by APCs thus
favoring an adaptive immune response against tumor
antigens. Interestingly, in the subgroup of patients who failed
to express ecto-CRT at the baseline level, anthracyclines
were unable to induce ecto-CRT either in vivo (Figure 1d) or
in vitro (data not shown). This suggests that these tumor
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Figure 3 Ecto-CRT is associated with enhanced T lymphocyte responses to autologous leukemic DCs. (a) Representative ﬂow cytometry analysis of LPS-matured
AMLblast-derived DCs(
AMLDC)deﬁnedas CD11c
þ HLA-DR
þ double-positivecells.ExpressionofCD80andCD40on AML-DCisalsodepicted.(b andc)Determinationof
IFNg levels in the supernatants from puriﬁed CD3
þ T lymphocytes co-cultured with autologous
AMLDC, autologous undifferentiated blast cells at diagnosis or medium as
control. Autologous monocyte-derived DCs (mDC) from HVs were co-cultured with puriﬁed autologous CD3
þ T lymphocytes or medium as control. Statistical analysis was
performed using a Wilcoxon matched-pairs test. Results were either plotted as means±S.E.M. b or on a patient-by-patient basis c. ns, nonsigniﬁcant
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Cell Death and Diseasecells have a defective CRT exposure pathway (Figure 1d)
that could not be induced and/or restored by induction
chemotherapy. In analogy, a previous observation was
made on neuroblastoma cells that were also refractory to
anthracyclin-induced CRT exposure unless the ER Ca
2þ
channel SERCA was blocked.
32
Although we were unable to identify any effect of
anthracyclines on CRT exposure on leukemic cells, we tested
thehypothesisthatecto-CRTmightbelinkedtoantitumorTh1
immune responses. As shown in Figure 3, this link exists.
Indeed, puriﬁed T lymphocytes from the ecto-CRT
pos group of
patients were capable of secreting IFNg in response to
autologous leukemic DCs, while ecto-CRT
neg group of
patients failed to do so. It is to be noted that lymphocytes
were isolated at diagnosis before any treatment, demonstrat-
ing that this antitumor immune response occurred ‘naturally’
(that is before treatment) in AML. How can the differences
between ecto-CRT
pos and ecto-CRT
neg patients with respect
to the antitumor immune response be explained? The ‘eat me’
and ‘don’t eat me’ signals expressed on the surface of tumor
cells might have a crucial role in determining the nature of
APC, thus ultimately inﬂuencing the polarization of the
immune response. Indeed, it is well accepted that distinct
DC subtypes not only control immunity but also regulate the
advent and the type of responses against self and non-self.
33
In humans, some DC sub-populations have been proposed to
secrete high levels of IL-12, thereby favoring Th1 polariza-
tion.
34 Human DC selectively expressing 6-sulfo LacNAc, an
O-linked carbohydrate modiﬁcation of PSGL-1, have recently
been identiﬁed in the blood and have been nicknamed
‘slanDC’ in reference to their speciﬁc marker (6-sulfo
LacNAc).
35,36 SlanDC account for the majority of DC in
human blood (0.6–2% of PBMCs) and have a phenotype
(6-sulfo LacNAcþ, CD1c-, CD11cþ, CD16þ, CD142,
C5aRþ and CD45RAþ) that differs from that of previously
described DC sub-populations.
37 SlanDC are the quantita-
tively most abundant IL-12p70-producing cells among blood
leukocytes. These ﬁndings emphasize the probable role of
slanDC in the induction and perpetuation of inﬂammation, as
this is also suggested by the high frequency of slanDC in
diseases characterized by local Th1-dominated inﬂammatory
response, such as psoriasis vulgaris and rheumatoid arthritis.
Interestingly, the maturation of and IL-12 production by
slanDC is controlled by CD47 expressed on erythrocytes
and SIRPa expressed on slanDC.
35 Hence, slanDC might
represent a good candidate for the APC that engulfs CD47
low
leukemiacells.Nonetheless,theexpressionofCRTreceptors
(such as CD91 and scavenger receptor class-A), on slanDC,
remains to be studied. It should be noted that another human
DC subtype, DC NK lectin group receptor-1
þ blood DC
antigen-3
þ DCs has recently been identiﬁed.
38 This DC
subtype efﬁciently internalizes antigenic material from necro-
tic cells, produces high levels of IL-12 and cross-presents
exogenous antigens to CD8
þ T cells, thus representing the
human equivalent of murine CD8a
þ DC.
38 However, the
relationship between these DC subtypes and their capacity to
internalize tumor cells expressing ecto-CRT remains elusive.
a
b
Figure 4 Correlation of ecto-CRT exposure and patient evolution. (a) Overall
survival. (b) Relapse-free survival for patients who achieved complete remission
after intensive chemotherapy (n¼15). The difference between ecto-CRT
pos and
ecto-CRT
neg is not statistically signiﬁcant (log-rank Mantel–Cox test; P¼0.5008)
Table 2 Clinical outcome
All CRT (+)
(n¼10)
CRT ( )
(n¼10)
Intensive chemotherapy, n 18 9 9
CR, n 15 7 8
Consolidation in CR 1
Chemotherapy only, n 11 5 6
HSC allograft, n 42 2
Relapse, n 62 4
Death total, n8 4 4
Death without CR, n 53 2
Death after relapse, n 21 1
Death of other cause, n 10 1
a
Median follow-up,
month (range)
13 (1–42) 29 (1–42) 10.3 (2–30)
Relapse-free survival in
(CR) patients (n¼15):
median, month*
32.5 10.3
Abbreviations: CR, complete remission; HSC, hematopoietic stem cell
aDeath of infectious cause during consolidation course
*Relapse-free survival: survival without relapse for patients who achieved CR
(n¼15)
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Cell Death and DiseaseTo conclude, we have identiﬁed cell surface exposure of
CRT on primary blasts from approximately half of the AML
patients. This CRT exposure occurs before chemotherapy
and is not further enhanced by anthracycline-based chemo-
therapy. Conversely, half of the patients’ blasts lacked CRT
exposure both before and after anthracyline treatment. We
demonstrated for the ﬁrst time a link between ecto-CRT
on the surface of malignant blasts and the secretion of IFNg
by autologous T lymphocytes confronted with them. On the
basis of these encouraging results, we will launch a large
prospective study to determine the prognostic and predictive
impact of ecto-CRT expression and that of its surrogate
marker, eIF2a phosphorylation.
Patients and Methods
Patients. Twenty patients, who were diagnosed with AML, were consecutively
admitted in the Hematology Department of the Institut Gustave Roussy in Villejuif,
France, between March 2008 and March 2009. Informed consent was obtained,
according to the Declaration of Helsinki, and the study was approved by the local
ethics committee (Comite ´ de Protection des Personnes (CPP) Ho ˆpital Bice ˆtre –
CALEX protocol, n1 ID RCB 2007-A01074-49, date 29 February 2008). The main
clinical and biological characteristics of the patients are summarized in Table 3.
Induction chemotherapy comprised one anthracycline (idarubicine or
daunorubicine) associated with cytarabine (except for two patients: one not
eligible for an intensive chemotherapy, and one who died in intensive care unit
before initiation of the treatment), followed by one to four courses of consolidation.
Onepatient, who was diagnosed with promyelocyticleukemia,also received ATRA.
An allograft of hematopoietic stem cells was performed for eligible patients (relapse
situation and high risk of relapse, based on cytogenetic and biomolecular results),
for whom a (genotypically or phenotypically) compatible donor was found.
Blood samples. Peripheral blood samples were obtained before the onset of
chemotherapyinallpatients.Asecondsamplewasdrawn2to6haftertheinitiation
of the intravenous chemotherapy. PBMC were separated on a Ficoll-gradient.
Flow cytometry. PBMCs were ﬁrst ﬁxed brieﬂy in 0.25% paraformaldehyde on
ice. Cells were directly labeled with an anti-CD45 monoclonal antibody (coupled to
APC, BD Biosciences, Le Pont de Claix, France). CD45 is highly expressed on
normal hematopoietic cells, yet poorly expressed on malignant blasts (CD45
dim).
The labeling of the membrane CRT was performed in two-step procedure: (i)
incubation with a rabbit anti-CRT antibody (Ozyme, Saint-Quentin-en-Yvelines,
France) (or rabbit serum as an isotypic control), then, after a washing step in cold
PBS, (ii) labeling with an anti-rabbit immunoglobulin coupled to FITC
(BD Biosciences). All these steps were performed on ice. The labeled PBMCs
were analyzed on a FACS Calibur cytoﬂuorometer (Becton Dickinson, Le Pont de
Claix, France) with a simultaneous discrimination of the live–dead cells using 7AAD
(amino-actinomycin D, BD Biosciences). CD47 expression was measured using an
antiCD47-phycoerythrineconjugate(BDBiosciences)whilegatingonCD45
highand
CD45
dim cells in order to discriminate normal from blast cells. FACS data were
analyzed with the help of FlowJo software (Tree Star, Inc., Ashland, OR, USA).
ELISA assay for the dosage of soluble CRT in sera of patients. A
sandwich ELISA assay was performed to detect CRT in the sera of patients before and
after chemotherapy. Brieﬂy, anti-CRT polyclonal (rabbit anti-CRT, Ozyme) diluted to 1/
1000
einPBS (pH¼7.2)supplementedwith100mMbicarbonate,wasincubatedin96-
well Maxisorp plates at 41C overnight. After washing (PBS supplemented with 0.05%
Tween),PBS2%humanserumalbuminwasaddedfor1hforsaturation.Afterwashing,
samples (diluted 1:10 in PBS plus 2% albumin) were added to the wells for 2h at room
temperature. After washing, a secondary anti-CRT (mouse anti-CRT, Abcam, Paris,
France; dilution 1/5000
e) was added (1h at room temperature). A goat anti-mouse
antibody coupled to horseradish peroxidase (Jackson Immunoresearch, Marseille,
France; dilution 1/5000
e) was added for 1h at room temperature and subsequently
washed. Revelation was done using TMB substrate (tetramethylbenzidine OptEIA, BD
Biosciences).Thereactionwasstoppedwith50mlof1MH 2SO4,andtheopticaldensity
was measured at 450nm. Patient samples were analyzed in triplicate and compared
with sera from HVs.
Leukemic DCs. DCs were derived from PBMC as previously described.
39
Brieﬂy, PBMCs were incubated at 371C in a ﬂask at 1.10
6 cells/cm
2 in culture
medium(AIM-V,Invitrogen,CergyPontoise,France);after2h,thesupernatantwas
discarded, and the adherent cells (mostly blasts cells) were cultured for 4 days in
AIM-V medium containing IL-4 (200IU/ml, Cellgenix, Clermont L’Herault, France)
and GM-CSF (1000IU/ml, Cellgenix). Lipopolysaccharide (1mg/ml, Sigma, Lyon,
France) was added on the last day before collection to induce DCs maturation.
The cells were collected and their immunophenotype was checked by
immunoﬂuorescene and ﬂow cytometry to conﬁrm the presence of DC markers
(anti-CD11c PC7, anti-HLA-DR Paciﬁc Blue, anti-CD40 FITC, anti-CD80 PE, all
from BD Bioscience).
Isolation of T lymphocytes. PBMCs from the diagnosis (before treatment)
were frozen after collection and isolation by Ficoll density gradient centrifugation.
After thawing, cells were labeled with anti-CD3 antibody (coupled to FITC, BD
Bioscience), and their viability was assessed using 7AAD. The labeled cells were
Table 3 Baseline clinical and biological characteristics of the patients
Variable
Age
o50 years 7 (35%)
Z50 years 13 (65%)
Median (years) 62
Range (years) 26–82
Sex
Male 9 (45%)
Female 11 (55%)
Peripheral-blood white cell count
o30.000/mm
3 10 (50%)
Z30.000/mm
3 10 (50%)
Median (10
9 cells/l) 180
Range (10
9 cells/l) 2.8–215
Blasts peripheral blood
Median (%) 51
Range (%) 3–85
De novo AML, n 16 (80%)
Of which n relapse AML at the inclusion 3 (15%)
Secondary AML
MPS/MDS, n 2 (10%)
Therapy related, n 3 (15%)
FAB classiﬁcation
AML 0 1 (5%)
AML 1 3 (15%)
AML 2 3 (15%)
AML 3 1 (5%)
AML 4 6 (30%)
AML 5 6 (30%)
AML 6 0 (0%)
AML 7 0 (0%)
Cytogenetic proﬁle
Favorable 4 (20%)
Intermediate 9 (45%)
Unfavorable 5 (25%)
Missing data 2 (10%)
Molecular characteristics
Isolated FLT3-ITD 3 (15%)
FLT3-ITD and NPM
# 1 (5%)
AML1/RUNX1 1 (5%)
Abbreviations: AML, acute myeloid leukemia; AML1/RUNX1, runt-related
transcription factor 1; FAB, Franco–Americano–British classiﬁcation;
FLT3-ITD, FLT3 internal tandem duplication; MPS/MDs, myeloproliferative/
myelodysplastic syndrome; NPM, nuclephosmine; WBC, white blood count
#One patient presented a NPM (nuclephosmine) mutation, but associated with
FLT3-ITD
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France), while discriminating the cells based on their size, granularity and
ﬂuorescence (CD3
þ and 7AAD
 ) allowing for the isolation of 495% pure T
lymphocytes.
In vitro stimulation of T lymphocytes. The leukemic DCs were incubated
with autologous T lymphocytes (LT) in 96-wells plates in triplicates, at a LT/DC ratio
of 10 to 1. IL-2 (10IU/ml, Proleukine from Novartis, Rueil-Malmaison, France) and
IL-7(5ng/ml,R&Dsystem,Minneapolis,MN,USA)wereaddedinthemedium.Asa
control, mDCs from HVs were incubated with autologous T lymphocytes. After 2
days,supernatants werecollectedandfrozenat  801Cuntil measurementof IFNg
by ELISA. We managed to realize this stimulation protocol for 15 of the 20 patients
(n¼8 for the ecto-CRT-negative group and n¼7 for the ecto-CRT-positive group
of patients); for the ﬁve other patients, we were unable to derive DC from blasts or
failed to obtain a sufﬁcient number of T lymphocytes from peripheral blood because
of a major lymphopenia at diagnosis. The control experiment was performed on ﬁve
HVs.StatisticalanalyseswereperformedusingtheWilcoxontestfornon-parametric
pairedvalues,with thehelpoftheGraphpadPrism5 software(GraphPadSoftware,
Inc., La Jolla, CA, USA).
Western blot analysis. Frozen blasts were thawed and washed with PBS
before lyses as previously described.
40 The protein content was measured using
the Protein Assay Kit (Bio-Rad, Marnes-la-Coquette, France) following the
manufacture’s instruction and 50mg of protein were separated onto NuPAGE
gels (Invitrogen) and transferred to Immobilion-PVDF membranes (Millipore Corp.,
Billerica, MA, USA). The membranes were incubated for 1h in TBS-Tween 20
(0.05%) containing 5% BSA. Primary antibodies speciﬁc for phosphorylated eIF2a
(Cell Signaling Technology, Danvers, MA, USA) and eIF2a (Cell Signaling
Technology) were incubated overnight at 41C and revealed with the appropriate
horseradish peroxidase-labeled secondary antibodies (SouthernBiotech,
Birmingham, AL, USA) by means of chemoluminiscent substrate (Pierce,
Rockford, IL, USA).
Confocalmicroscopy. Primarycellsfroman AMLpatienthavebeenwashed
with PBS before immunostaining using anti-CD45 antibody (FITC coupled from BD
Bioscience). The cells have been washed with PBS and subsequently ﬁxed with
0.25%ofPFAbeforestainingofcellsurfaceCRTusingmousemonoclonalantibody
(clone fmc75, ab22683, Abcam) followed by anti-mouse AlexaFluor 568 (Molecular
Probes (Cergy Pontoise, France), Invitrogen) in PBS supplemented with 5% BSA.
The nuclei were stained with DAPI before image acquisition by means of a TSC-
SPE confocal microscope (Leica Microsystems GmbH, Wetzlar, Germany)
equipped with a 63X/1.15 objective (Olympus America, Center Valley, PA, USA).
Signals from different probes were acquired in sequential scan mode and overlays
have been done with Photoshop.
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